These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29680480)

  • 1. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications.
    Modi PK; Wang Y; Kirk PS; Dupree JM; Singer EA; Chang SL
    Urology; 2018 Jul; 117():50-56. PubMed ID: 29680480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
    DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
    JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
    BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS
    Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
    Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
    Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
    Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
    BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
    Minhas R; Tadrous M; Elterman D; Gomes T
    Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
    Morse E; Hanna J; Mehra S
    Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of solifenacin and mirabegron for overactive bladder management.
    Cornu JN
    BJU Int; 2015 Oct; 116(4):498-9. PubMed ID: 26350574
    [No Abstract]   [Full Text] [Related]  

  • 18. Overactive bladder medication: Anticholinergics versus mirabegron by specialty.
    Sripad AA; Raker CA; Sung VW
    Urologia; 2022 Nov; 89(4):511-516. PubMed ID: 35195050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
    Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
    Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
    Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.